We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amgen (AMGN) Files for KRAS Inhibitor for Lung Cancer in Europe
Read MoreHide Full Article
Amgen, Inc. (AMGN - Free Report) submitted a marketing authorization application (MAA), seeking approval of its investigational KRAS inhibitor, sotorasib in Europe for previously treated locally advanced/metastatic non-small-cell lung cancer (“NSCLC”) in patients with KRAS G12C mutation.
Amgen filed a new drug application (NDA) to the FDA for sotorasib last week. The NDA and MAA filings were based on positive data from the phase II CodeBreaK 100 study, which evaluated sotorasib in patients with advanced NSCLC whose disease progressed despite prior treatment with chemotherapy and/or immunotherapy. Data from the study showed that treatment with sotorasib led to deep and durable anticancer activity with a positive benefit-risk profile in the given patient population.
Notably, tumors characterized by KRAS mutations are commonly associated with poor prognosis and resistance to therapy.
Per the company, KRAS G12C mutations are present in approximately 13% of NSCLC adenocarcinomas. There is a high unmet medical need for the given indication as NSCLC patients with KRAS G12C mutation who have failed first-line treatment have limited treatment options available. Annually, approximately 33,000 new patients in the EU are diagnosed with KRAS G12C-mutated NSCLC. If successfully developed and approved, sotorasib will be the first approved targeted therapy for this patient population.
Amgen’s stock has declined 8.3% this year so far against an increase of 10.1% for the industry.
Sotorasib is also being evaluated in a phase II monotherapy study in advanced colorectal cancer patients whose top-line data are expected to be released next year. Amgen is also conducting phase Ib combination studies on sotorasib with PD-1, MEK and other targeted therapies.
We note that many companies have KRAS G12C inhibitors in their pipelines being developed for various cancer indications. Apart from Amgen, Eli Lilly (LLY - Free Report) and J&J (JNJ - Free Report) have KRAS G12C inhibitor candidates in their pipelines. Small biotech, Mirati Therapeutics has adagrasib, a KRAS G12C inhibitor, in its pipeline.
In a separate press release Amgen announced that it is out-licensing rights to AMG 634, an investigational therapy for tuberculosis and leprosy, to Medicines Development for Global Health (MDGH), a non-profit biotech. Amgen had acquired AMG 634 as part of the Otezla deal from Celgene in 2019. MDGH will now take care of AMG 634’s development/commercialization.
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Image: Shutterstock
Amgen (AMGN) Files for KRAS Inhibitor for Lung Cancer in Europe
Amgen, Inc. (AMGN - Free Report) submitted a marketing authorization application (MAA), seeking approval of its investigational KRAS inhibitor, sotorasib in Europe for previously treated locally advanced/metastatic non-small-cell lung cancer (“NSCLC”) in patients with KRAS G12C mutation.
Amgen filed a new drug application (NDA) to the FDA for sotorasib last week. The NDA and MAA filings were based on positive data from the phase II CodeBreaK 100 study, which evaluated sotorasib in patients with advanced NSCLC whose disease progressed despite prior treatment with chemotherapy and/or immunotherapy. Data from the study showed that treatment with sotorasib led to deep and durable anticancer activity with a positive benefit-risk profile in the given patient population.
Notably, tumors characterized by KRAS mutations are commonly associated with poor prognosis and resistance to therapy.
Per the company, KRAS G12C mutations are present in approximately 13% of NSCLC adenocarcinomas. There is a high unmet medical need for the given indication as NSCLC patients with KRAS G12C mutation who have failed first-line treatment have limited treatment options available. Annually, approximately 33,000 new patients in the EU are diagnosed with KRAS G12C-mutated NSCLC. If successfully developed and approved, sotorasib will be the first approved targeted therapy for this patient population.
Amgen’s stock has declined 8.3% this year so far against an increase of 10.1% for the industry.
Sotorasib is also being evaluated in a phase II monotherapy study in advanced colorectal cancer patients whose top-line data are expected to be released next year. Amgen is also conducting phase Ib combination studies on sotorasib with PD-1, MEK and other targeted therapies.
We note that many companies have KRAS G12C inhibitors in their pipelines being developed for various cancer indications. Apart from Amgen, Eli Lilly (LLY - Free Report) and J&J (JNJ - Free Report) have KRAS G12C inhibitor candidates in their pipelines. Small biotech, Mirati Therapeutics has adagrasib, a KRAS G12C inhibitor, in its pipeline.
In a separate press release Amgen announced that it is out-licensing rights to AMG 634, an investigational therapy for tuberculosis and leprosy, to Medicines Development for Global Health (MDGH), a non-profit biotech. Amgen had acquired AMG 634 as part of the Otezla deal from Celgene in 2019. MDGH will now take care of AMG 634’s development/commercialization.
Amgen currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Click here for the 6 trades >>